home / stock / cwbr / cwbr news

CWBR News and Press, CohBar Inc. From 11/01/21

Stock Information
Company Name: CohBar Inc.
Stock Symbol: CWBR
Market: OTC
Website: cohbar.com
Menu
CWBR CWBR Quote CWBR Short CWBR News CWBR Articles CWBR Message Board
Get CWBR Alerts

News, Short Squeeze, Breakout and More Instantly...
CWBR - 5 Top Penny Stocks To Watch Under $1 After CSCW Stock Explodes

There are so many traders looking for the best penny stocks 2021 has to offer. Something that many are finding out, however, is that without a plan, you can get lost in the noise. With thousands of stocks hitting scanners and millions of traders giving their 2 cents, it can become d...
CWBR - CohBar to Announce 2021 Third Quarter Financial Results and Provide Business Update on November 15, 2021

MENLO PARK, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 20...

CWBR - CohBar slumps ~32% on pricing of ~$15M stock, warrants offering

CohBar (NASDAQ:CWBR) priced a public offering of ~20.83M common shares and accompanying warrants to buy ~20.83M shares at $0.72/share and warrant. Each warrant will have an exercise price of $0.72/share. The gross proceeds from the offering are expected to be ~$15M. CohBar intends to use the ...

CWBR - CohBar Announces CB4211 Phase 1a/1b Results Selected for Late Breaker Presentation at The Liver Meeting® 2021

MENLO PARK, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that data from its CB4211 Phase 1a/1b clinical study ha...
CWBR - CohBar to Present at H.C. Wainwright 5th Annual NASH Investor Conference

MENLO PARK, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, wi...

CWBR - Stocks To Watch on Wall Street Today (BLBX, CWBR, FAMI, SONN, LBPS, JSPR, OPGN, ARQQ, ENG, OLB, ADVM, HIVE)

This morning DOW has shed over 100 points and it looks like October will be no different than the volatile September. A surge in rates to end September knocked highly valued tech stocks. The 10-year Treasury yield was higher Monday, trading around 1.49%. Let’s take a look at some of th...

CWBR - CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent...
CWBR - CohBar Granted U.S. Patent Covering CB4211 Compositions and Use for Treating Nonalcoholic Steatohepatitis (NASH)

MENLO PARK, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the United States Patent and Trademark Office has gran...

CWBR - CohBar to Present at Upcoming Investor Conferences

MENLO PARK, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Dr. Joseph Sarret, w...

CWBR - CohBar Appoints Carol Nast to Its Board of Directors

MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Carol Nast as an independent directo...
Previous 10 Next 10